AI-generated summary
This review examines whether transcranial photobiomodulation, which uses low-power red and near-infrared light, could help treat major depressive disorder. The authors report some evidence that near-infrared light delivered in a 10-Hz pulsed mode appears promising, but they state that further studies are needed to establish safety and an effective treatment protocol.
- Who or what was studied
- Patients with major depressive disorder
- Limits stated in the abstract
- The abstract describes a narrative review, provides only limited evidence, and states that safety and effective protocols remain to be determined.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on degruyter.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Transcranial photobiomodulation, Near-infrared, Adenosine triphosphate, Neuroinflammation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.